Perspective TherapeuticsvsThermo Fisher Scientific

CATX and TMO stock compared: price, dividend, valuation and results, from SEC filings.

CATX

Perspective Therapeutics, Inc.

$0.75

Value $91M

-3.85%
CATX's page

TMO

Thermo Fisher Scientific Inc

$669.54

Value $249B

-2.79%
TMO's page

Perspective Therapeutics (CATX) has a market value of $91M and Thermo Fisher Scientific (TMO) $249B. Over the last year, with dividends, CATX moved -67.4% and TMO +17.1%. Dividend yield: CATX none, TMO 0.27%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CATX$91M

    TMO$249B

    TMO is 2,732 times CATX

  • Revenue, 12 months

    CATX–

    TMO$47.4B

  • Net income, 12 months

    CATX-$123M

    TMO$7.1B

  • Operating margin

    CATX–

    TMO17.9%

  • ROIC

    CATX-43.0%

    TMO8.2%

    51.2 points apart

  • P/E

    CATX–

    TMO35.2

  • Dividend yield

    CATX0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    CATX-84.7%

    TMO+6.8%

    91.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CATX-84.7%

TMO+6.8%

020020222023202420252026
Returns by period
PeriodCATXWith dividendsTMOWith dividends
1 year since November 19, 2025-67.4%Price -67.4%+17.1%Price +16.7%
3 years since November 20, 2023-70.0%-33.1% a yearPrice -70.0%+44.1%+13.0% a yearPrice +42.7%
5 years since November 19, 2021-84.7%-31.3% a yearPrice -84.7%+6.8%+1.3% a yearPrice +5.3%
10 years since November 21, 2016-86.8%-18.4% a yearPrice -86.8%+371.2%+16.8% a yearPrice +358.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CATXPerspective TherapeuticsTMOThermo Fisher Scientific

Valuation

CATXTMO
Valuation
Price$0.75$669.54
Market value$91M$249B
Enterprise value (EV)–$284B
P/E–35.2
P/E, 5-year median–32.7
P/B0.34.5
EV/EBIT–33.5
Free cash flow yield–3.1%

Results and growth

CATXTMO
Results and growth
Revenue, 12 months–$47.4B
Net income, 12 months-$123M$7.1B
Free cash flow, 12 months-$139M$7.6B
Earnings per share, 12 months-$1.25$18.96
Revenue growth, year on year–3.9%
Revenue growth a year, past-24.7%over 5 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

CATXTMO
Margins and returns on capital
Gross margin––
Operating margin–17.9%
Net margin–14.9%
ROIC-43.0%8.2%
ROE-43.4%13.4%

Balance sheet

CATXTMO
Balance sheet
Cash$202M$6.1B
Total debt$3.7M$41.4B
Net debt / EBITDA–3.7
Interest cover–5.5×

Dividends and buybacks

CATXTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CATX or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Perspective Therapeutics or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($249B) is about 2,732.4 times Perspective Therapeutics ($91M), at today's prices.

How did CATX and TMO stock do over the last 10 years?

Since November 21, 2016, CATX's price moved -86.8% and TMO's +358.1%. With dividends: CATX -86.8% (-18.4% a year), TMO +371.2% (+16.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, CATX or TMO?

The dividend yield at today's price is none for Perspective Therapeutics and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which is the better investment, Perspective Therapeutics or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.